Pierre L. Triozzi

Hematology
1 Medical Ctr Blvd Fl 3
Winston Salem, NC 27103

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications

Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical Trial.

Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical Trial.

Journal: JAMA otolaryngology-- head & neck surgery
Published: June 18, 2026

Enhancing Patient Lymphocyte Response to Peritoneal Malignancies Using a Personalized Immunocompetent Microfluidic Co-Culture Platform.

Enhancing Patient Lymphocyte Response to Peritoneal Malignancies Using a Personalized Immunocompetent Microfluidic Co-Culture Platform.

Journal: bioRxiv : the preprint server for biology
Published: February 27, 2026

Cancer-intrinsic SIRPα Signaling Triggers Mitochondrial Fission and Immune Tolerance to Promote TNBC Breast-to-Brain Metastasis.

Cancer-intrinsic SIRPα Signaling Triggers Mitochondrial Fission and Immune Tolerance to Promote TNBC Breast-to-Brain Metastasis.

Journal: Neuro-oncology
Published: February 25, 2026

Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance status.

Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance status.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 23, 2025

Treatment Options for Brain Metastases.

Treatment Options for Brain Metastases.

Journal: Current treatment options in oncology
Published: March 04, 2024

Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma.

Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma.

Journal: Cancer research communications
Published: October 03, 2023

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer.

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer.

Journal: Future oncology (London, England)
Published: May 18, 2023

Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer.

Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer.

Journal: Therapeutic advances in medical oncology
Published: March 23, 2023

Patterns of Failure Outcomes for Combination of Stereotactic Radiosurgery and Immunotherapy for Melanoma Brain Metastases.

Patterns of Failure Outcomes for Combination of Stereotactic Radiosurgery and Immunotherapy for Melanoma Brain Metastases.

Journal: Neurosurgery practice
Published: July 25, 2022

Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response.

Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response.

Journal: Journal for immunotherapy of cancer
Published: June 12, 2022

A First Suspected Case of Fibrosing Mediastinitis After Anti-PD-1 Therapy.

A First Suspected Case of Fibrosing Mediastinitis After Anti-PD-1 Therapy.

Journal: JACC. Case reports
Published: May 16, 2022

Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors.

Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors.

Journal: Cancer
Published: February 24, 2022
Showing 1-12 of 64

Last Updated: 09/26/2026